Teva price target raised to $25 from $22 at Barclays | Nasdaq

Teva Price Target Raised To $25 From $22 At Barclays | Nasdaq

2 weeks from now

Oct 23, 2024  · TEVA. Barclays raised the firm’s price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced Olanzapine into its model, noting TEV-749’s sales ...

nasdaq.com

Teva Pharmaceutical (TEVA) Receives A Buy From Barclays

2 weeks from now

Oct 23, 2024  · Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $25.00. The company’s shares …

businessinsider.com

Barclays Reaffirms Their Buy Rating On Teva Pharmaceutical (TEVA)

2 weeks from now

Nov 6, 2024  · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00.The company’s …

businessinsider.com

Teva Pharmaceutical (TEVA) Gets A Buy From Barclays

2 weeks from now

3 days ago  · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s …

businessinsider.com

Barclays Lifts Teva Pharma Stock Target On Sales Potential

2 weeks from now

Oct 23, 2024  · TEVA. 1.26%. Barclays has updated its outlook on Teva Pharmaceutical Industries Limited (NYSE: NYSE: TEVA), increasing the price target to $25.00 from the previous $22.00 …

investing.com

Teva Pharmaceutical Industries (TEVA) Stock Forecast & Price Target

2 weeks from now

1 day ago  · According to the 9 analysts' twelve-month price targets for Teva Pharmaceutical Industries, the average price target is $19.67. The highest price target for TEVA is $26.00, …

marketbeat.com

Teva Pharmaceutical Indus (NYSE:TEVA) Stock, Analyst Ratings, …

2 weeks from now

5 days ago  · Teva Pharmaceutical Industries Ltd has a consensus price target of $17.7 based on the ratings of 12 analysts. The high is $26 issued by UBS on September 3, 2024. The low is …

benzinga.com

A Closer Look At 4 Analyst Recommendations For Teva ... - Nasdaq

2 weeks from now

Oct 23, 2024  · Insights from analysts' 12-month price targets are revealed, presenting an average target of $22.75, a high estimate of $26.00, and a low estimate of $18.00.

nasdaq.com

Veeva Price Target Raised To $260 From $240 At Barclays - Nasdaq

2 weeks from now

6 days ago  · Barclays raised the firm’s price target on Veeva (VEEV) to $260 from $240 and keeps an Overweight rating on the shares. The firm says the company set a new long-term …

nasdaq.com

JPMorgan Chase & Co. Boosts Teva Pharmaceutical Industries …

2 weeks from now

Oct 21, 2024  · Barclays upped their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an "overweight" rating in a research report on Thursday, …

marketbeat.com

Coherent Corp. (COHR) Price Target Raised To $105 By Barclays On ...

2 weeks from now

1 day ago  · Coherent Corp. (COHR) Price Target Raised to $105 by Barclays on Improved Revenue Outlook Despite Margin Pressures. ... Nasdaq Futures. 21,148.25-41.25 (-0.19%) …

yahoo.com

Barclays Reaffirms Their Buy Rating On Teva Pharmaceutical (TEVA)

2 weeks from now

Jun 9, 2023  · Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday and set a price target of $14.00. The company’s shares …

businessinsider.com

Sivik Global Healthcare LLC Sells 30,000 Shares Of Teva

2 weeks from now

19 hours ago  · Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a report on …

marketbeat.com

Regions Financial Price Target Raised To $25 From $22 At Barclays

2 weeks from now

Oct 18, 2024  · Barclays analyst Jason Goldberg raised the firm’s price target on Regions Financial (RF) to $25 from $22 and keeps an Underweight rating on the shares. The bank’s …

nasdaq.com

Analysts Offer Insights On Healthcare Companies: Teva …

2 weeks from now

May 13, 2024  · In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical, with a price target of $20.00. The company’s shares closed …

businessinsider.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold …

2 weeks from now

4 days ago  · Barclays boosted their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, October 23rd. …

marketbeat.com

First Quantum Minerals Upgraded To Overweight From Equal

2 weeks from now

2 days ago  · Barclays upgraded First Quantum Minerals (FQVLF) to Overweight from Equal Weight with a price target of C$25, up from C$18. The firm says higher copper prices are …

nasdaq.com

Excelerate Energy Price Target Raised To $29 From $25 At Northland …

2 weeks from now

3 days ago  · Northland analyst Bobby Brooks raised the firm’s price target on Excelerate Energy (EE) to $29 from $25 and keeps an Outperform rating on the shares. Excelerate "continues to …

nasdaq.com

First Watch Restaurant Price Target Raised To $23 From $22 At

2 weeks from now

3 days ago  · Piper Sandler raised the firm’s price target on First Watch Restaurant (FWRG) to $23 from $22 and keeps an Overweight rating on the shares following quarterly results. Overall, …

nasdaq.com

Teva Presents New Tardive Dyskinesia Data At Psych Congress

2 weeks from now

Nov 1, 2024  · Teva price target raised to $25 from $22 at Barclays Teva call volume above normal and directionally bullish Teva, Alvotech announce U.S. FDA approval of presentation of …

nasdaq.com

Expert Outlook: Norwegian Cruise Line Through The Eyes Of 15

2 weeks from now

2 days ago  · The average target is $27.4, accompanied by a high estimate of $36.00 and a low estimate of $19.00. Surpassing the previous average price target of $22.77, the current …

nasdaq.com

First Watch Announces Pricing Of 8M Shares At $19.95 In ... - Nasdaq

2 weeks from now

2 days ago  · The shares have been offered at a price to the public of $19.95 per share. The Offering is expected to close on November 13, 2024, subject to customary closing conditions.

nasdaq.com